<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system</dc:title>
  <dc:creator>Thiam, M.</dc:creator>
  <dc:creator>Diop-Ndiaye, H.</dc:creator>
  <dc:creator>Diouf, A. D.</dc:creator>
  <dc:creator>/Vidal, Nicole</dc:creator>
  <dc:creator>Ndiaye, O.</dc:creator>
  <dc:creator>Ndiaye, I.</dc:creator>
  <dc:creator>Ngom-Gueye, N. F.</dc:creator>
  <dc:creator>Diallo, S.</dc:creator>
  <dc:creator>Diongue, O. D.</dc:creator>
  <dc:creator>Camara, M.</dc:creator>
  <dc:creator>Seck, A.</dc:creator>
  <dc:creator>Mboup, S.</dc:creator>
  <dc:creator>Toure-Kane, C.</dc:creator>
  <dc:description>In this study, we investigated the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations and genetic variability among Senegalese patients undergoing highly active antiretroviral therapy (ART) in the public health system. We conducted a cross-sectional study of 72 patients with suspected therapeutic failure. HIV-1 genotyping was performed with Viroseq HIV-1 Genotyping System v2.0 or the procedure developed by the ANRS AC11 resistance study group, and a phylogenetic analysis was performed. The median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log(10) copies/ml. The first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV) or NRTIs plus nevirapine (NVP) (54/72 patients; 75%), and the second-line therapy was NRTIs plus a protease inhibitor (PI/r) (18/72; 25%). Fifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. The drug resistance rates were 72.22 and 88.89% for the first-line and second-line ARTs, respectively. In NRTI mutations, thymidine analog mutations (TAMs) were found in 50.79% and the M184V mutation was found in 34.92% of the samples. For non-NRTI resistance, we noted a predominance of the K103N mutation (46.27%). For PI/r, several cases of mutations were found with a predominance of M46I and L76V/F at 24% each. The phylogenetic analysis revealed CRF02_AG as the predominant circulating recombinant form (43/72; 59.72%). We found a high prevalence of resistance mutations and a high rate of TAMs among Senegalese patients in the public health system. These findings emphasize the need to improve virological monitoring in resource-limited settings.</dc:description>
  <dc:date>2013</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/PAR00010187</dc:identifier>
  <dc:identifier>PAR00010187</dc:identifier>
  <dc:identifier>Thiam M., Diop-Ndiaye H., Diouf A. D., Vidal Nicole, Ndiaye O., Ndiaye I., Ngom-Gueye N. F., Diallo S., Diongue O. D., Camara M., Seck A., Mboup S., Toure-Kane C.. HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. 2013, 51 (2),  578-584</dc:identifier>
  <dc:language>EN</dc:language>
  <dc:coverage>SENEGAL</dc:coverage>
</oai_dc:dc>
